Current landscape and future prospects of RET and ROS1 targets

Zhang, Hai-Long1; Kong, Qian2

2023-09-01

10.4155/ppa-2023-0011

PHARMACEUTICAL PATENT ANALYST   Impact Factor & Quartile

2046-8954

2046-8962

RET and ROS1 are becoming key targets for targeted therapy. To show current landscape of ROS1 and RET targets, a patent analysis was performed. The present results indicated that inhibitor structures of ROS1 target demonstrated unique elements compared with inhibitor structures of RET or BRAF targets. Our study was the first time to uncover that a number of inhibitor structures of ROS1 target contained sulfur and boron elements. The inhibitors of RET target could be developed for treatment of various cancers, including lung cancer, thyroid cancer, and other solid tumor, while the inhibitors of ROS1 target are virtually developed for treatment of lung cancer. Our findings provide a new insight for drug discovery of ROS1 and RET target.

cancer patent patent landscape RET ROS1 targeted drugs

ESCI

English

Others

Pharmacology & Pharmacy

Pharmacology & Pharmacy

WOS:001062410400002

Newlands Press Ltd

Web of Science

1.Cent Int Intellectual Property Baotou Co Ltd, Baotou 014030, Peoples R China
2.Southern Univ Sci & Technol, Coll Sci, Dept Chem, Shenzhen 518055, Peoples R China

Zhang, Hai-Long,Kong, Qian. Current landscape and future prospects of RET and ROS1 targets[J]. PHARMACEUTICAL PATENT ANALYST,2023.

Zhang, Hai-Long,&Kong, Qian.(2023).Current landscape and future prospects of RET and ROS1 targets.PHARMACEUTICAL PATENT ANALYST.

Zhang, Hai-Long,et al."Current landscape and future prospects of RET and ROS1 targets".PHARMACEUTICAL PATENT ANALYST (2023).